Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
TORL Biotherapeutics LLC
TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026
June 18, 2026
TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer and Evolves Leadership for Next Phase of Growth
May 7, 2026